AstraZeneca PLC (AZN)vsBruker Corporation (BRKR)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
BRKR
Bruker Corporation
$44.16
+0.98%
HEALTHCARE · Cap: $6.44B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1659% more annual revenue ($60.44B vs $3.44B). AZN leads profitability with a 17.2% profit margin vs -0.3%. BRKR appears more attractively valued with a PEG of 1.52. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
BRKR
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Margin of Safety
+27.9%
Fair Value
$58.89
Current Price
$44.16
$14.73 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Expensive relative to growth rate
Weak financial health signals
ROE of -0.4% — below average capital efficiency
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : BRKR
The strongest argument for BRKR centers on Price/Book.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : BRKR
The primary concerns for BRKR are PEG Ratio, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while BRKR is a turnaround play — different risk/reward profiles.
BRKR carries more volatility with a beta of 1.12 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 42/100), backed by strong 17.2% margins and 12.5% revenue growth. BRKR offers better value entry with a 27.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Bruker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Billerica, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?